Gastroprotection in Methotrexate Patients

Recommended Gastroprotective Agents

The American College of Cardiology recommends standard-dose H2-receptor antagonists, such as famotidine 40 mg twice daily, for gastric protection in patients receiving methotrexate, as they effectively reduce duodenal ulcers 1
The American Heart Association suggests that double-dose H2-receptor antagonists, such as famotidine 80 mg daily, are effective against both gastric and duodenal ulcers in high-risk patients 1
The American Gastroenterological Association recommends assessing GI bleeding risk factors, including prior GI bleeding, advanced age, and concurrent NSAIDs or anticoagulants, to determine the appropriate gastroprotective strategy 2

For patients with low-to-moderate GI risk, the European Society of Cardiology recommends using famotidine 40 mg twice daily or ranitidine 300 mg daily, with no routine gastroprotection needed if no risk factors are present 3
For high GI risk patients, the American College of Gastroenterology suggests using double-dose H2-receptor antagonists and testing and treating H. pylori if present 3

Misoprostol 200 μg four times daily reduces NSAID-related ulcer complications by approximately 40%, but has significant side effects and lacks clinical data on its use with methotrexate 1
Sucralfate may reduce pneumonia risk compared to acid-suppressing agents, but efficacy data for methotrexate patients is absent 4, 5